

# Jeffrey J Gaynor

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6992611/publications.pdf>

Version: 2024-02-01

52  
papers

1,603  
citations

361413

20  
h-index

302126

39  
g-index

53  
all docs

53  
docs citations

53  
times ranked

1483  
citing authors

#	ARTICLE	IF	CITATIONS
1	Graft Failure Due to Nonadherence among 150 Prospectively-Followed Kidney Transplant Recipients at 18 Years Post-transplant: Our Results and Review of the Literature. <i>Journal of Clinical Medicine</i> , 2022, 11, 1334.	2.4	3
2	An explanation for the unmitigated disparity in patient survival between Black and White liver transplant recipients. <i>American Journal of Transplantation</i> , 2022, , .	4.7	0
3	Creating a Single Inflow Orifice From Living Donor Kidney Allografts With Multiple Renal Arteries. <i>Transplant International</i> , 2022, 35, 10212.	1.6	4
4	Predictors of Kidney Delayed Graft Function and Its Prognostic Impact following Combined Liver&#x2013;Kidney Transplantation: A Recent Single-Center Experience. <i>Journal of Clinical Medicine</i> , 2022, 11, 2724.	2.4	0
5	Response to systemic therapy in locally advanced and metastatic renal cell carcinoma: can it be predicted?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 629-639.	2.4	0
6	Midline Rotation of the Right Renal Hilum During Hand-Assisted Laparoscopic Living Donor Nephrectomy. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2021, 25, e2021.00018.	1.1	2
7	Results of a previously unreported extravesical ureteroneocystostomy technique without ureteral stenting in 500 consecutive kidney transplant recipients. <i>PLoS ONE</i> , 2021, 16, e0244248.	2.5	12
8	Evidence to support a drain-free strategy in kidney transplantation using a retrospective comparison of 500 consecutively transplanted cases at a single center. <i>BMC Surgery</i> , 2021, 21, 74.	1.3	4
9	Renal Cell Carcinoma with or without Tumor Thrombus Invading the Liver, Pancreas and Duodenum. <i>Cancers</i> , 2021, 13, 1695.	3.7	4
10	Clinical Outcomes Following Single vs. Multiple Vessel Living-Donor Kidney Transplantation: A Retrospective Comparison of 210 Patients. <i>Frontiers in Surgery</i> , 2021, 8, 693021.	1.4	5
11	Adrenal tumors of different types with or without tumor thrombus invading the inferior vena cava: An evaluation of 33 cases. <i>Surgical Oncology</i> , 2021, 37, 101544.	1.6	4
12	No Benefit of Prophylactic Surgical Drainage in Combined Liver and Kidney Transplantation: Our Experience and Review of the Literature. <i>Frontiers in Surgery</i> , 2021, 8, 690436.	1.4	1
13	Challenging Cases of Renal Cell Cancers With or Without Tumor Thrombus During the Covid-19 Pandemic. <i>Anticancer Research</i> , 2021, 41, 335-340.	1.1	0
14	Surgical Management of Upper Urinary Tract Urothelial Cell Carcinoma with Venous Tumor Thrombus: A Liver Transplant-Based Approach. <i>Journal of Clinical Medicine</i> , 2021, 10, 5964.	2.4	0
15	Use of pediatric donor en bloc kidneys along with bladder segment in pediatric liver&#x2013;kidney and multivisceral&#x2013;kidney transplantation. <i>Pediatric Transplantation</i> , 2020, 24, e13596.	1.0	4
16	Randomized trial of 3 maintenance regimens (TAC/SRL vs. TAC/MMF vs. CSA/SRL) with low&#x2013;dose corticosteroids in primary kidney transplantation: 18&#x2013;year results. <i>Clinical Transplantation</i> , 2020, 34, e14123.	1.6	8
17	Association of Alemtuzumab Induction With a Significantly Lower Incidence of GVHD Following Intestinal Transplantation: Results of 445 Consecutive Cases From a Single Center. <i>Transplantation</i> , 2020, 104, 2179-2188.	1.0	9
18	Association of More Intensive Induction With Less Acute Rejection Following Intestinal Transplantation: Results of 445 Consecutive Cases From a Single Center. <i>Transplantation</i> , 2020, 104, 2166-2178.	1.0	11

#	ARTICLE	IF	CITATIONS
19	Deceased donor kidney transplant in a 70-year-old Jehovah's Witness patient: to transplant or not to transplant—a case report. <i>Annals of Translational Medicine</i> , 2020, 8, 1249-1249.	1.7	0
20	Extraperitoneal pediatric kidney transplantation of adult renal allograft using an en-bloc native liver and kidney mobilization technique. <i>BMC Pediatrics</i> , 2020, 20, 526.	1.7	5
21	Pulmonary tumor embolization as early manifestation in patients with renal cell carcinoma and tumor thrombus: Perioperative management and outcomes. <i>Journal of Cardiac Surgery</i> , 2019, 34, 1018-1023.	0.7	19
22	Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1983-1992.	1.0	18
23	Roux-en-Y gastric bypass is an effective bridge to kidney transplantation: Results from a single center. <i>Clinical Transplantation</i> , 2018, 32, e13232.	1.6	22
24	Indications, complications, and outcomes following surgical management of locally advanced and metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 237-250.	2.4	9
25	The Importance of Using Serially Measured Tacrolimus Clearance Values, Especially During the Early Posttransplantation Period. <i>Transplantation</i> , 2018, 102, e42-e43.	1.0	1
26	Clinical depression as an unfavorable prognostic factor following kidney transplantation-How can we explain it?. <i>Transplant International</i> , 2018, 31, 14-16.	1.6	1
27	Antibody-mediated rejection implies a poor prognosis in kidney transplantation: Results from a single center. <i>Clinical Transplantation</i> , 2018, 32, e13392.	1.6	4
28	Inferior Vena Cava System Anomalies: Surgical Implications. <i>Current Urology Reports</i> , 2017, 18, 10.	2.2	20
29	Randomized trial of rATg/Daclizumab vs. rATg/Alemtuzumab as dual induction therapy in renal transplantation: Results at 8years of follow-up. <i>Transplant Immunology</i> , 2017, 40, 42-50.	1.2	13
30	Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation. <i>Transplant International</i> , 2016, 29, 216-226.	1.6	48
31	Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant. <i>Diabetologia</i> , 2015, 58, 334-345.	6.3	29
32	Multivariable risk of developing new onset diabetes after transplant—results from a single-center study of 481 adult, primary kidney transplant recipients. <i>Clinical Transplantation</i> , 2015, 29, 301-310.	1.6	22
33	Predictors of reduced tacrolimus dose and trough level through 36 months post-transplant among 578 adult primary kidney transplant recipients. <i>Clinical Transplantation</i> , 2014, 28, 470-478.	1.6	2
34	Randomized Trial of Three Induction Antibodies in Kidney Transplantation. <i>Transplantation</i> , 2014, 97, 1128-1138.	1.0	33
35	Lack of clinical association and effect of peripheral WBC counts on immune cell function test in kidney transplant recipients with T-cell depleting induction and steroid-sparing maintenance therapy. <i>Transplant Immunology</i> , 2014, 30, 88-92.	1.2	10
36	Graft Failure Due to Noncompliance Among 628 Kidney Transplant Recipients With Long-term Follow-up. <i>Transplantation</i> , 2014, 97, 925-933.	1.0	65

#	ARTICLE	IF	CITATIONS
37	Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation. <i>Transplant Immunology</i> , 2011, 25, 104-111.	1.2	26
38	Randomized Trial of Dual Antibody Induction Therapy With Steroid Avoidance in Renal Transplantation. <i>Transplantation</i> , 2011, 92, 1348-1357.	1.0	20
39	Randomized Trial of Mycophenolate Mofetil Versus Enteric-Coated Mycophenolate Sodium in Primary Renal Transplantation With Tacrolimus and Steroid Avoidance: Four-Year Analysis. <i>Transplantation</i> , 2011, 91, 1198-1205.	1.0	22
40	Addition of anti-CD25 to thymoglobulin for induction therapy: delayed return of peripheral blood CD25-positive population. <i>Clinical Transplantation</i> , 2011, 25, E132-5.	1.6	33
41	Randomized Trial of Immunosuppressive Regimens in Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1758-1768.	6.1	72
42	Effect of Kidney Transplantation on Outcomes among Patients with Hepatitis C. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1152-1160.	6.1	128
43	Favorable Outcomes With Machine Perfusion and Longer Pump Times in Kidney Transplantation: A Single-Center, Observational Study. <i>Transplantation</i> , 2010, 90, 882-890.	1.0	47
44	A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance) in renal transplantation. <i>Transplantation</i> , 2008, 22, 200-210.	1.6	97
45	Randomized Trial of Mycophenolate Mofetil Versus Enteric-Coated Mycophenolate Sodium in Primary Renal Transplant Recipients Given Tacrolimus and Daclizumab/Thymoglobulin: One Year Follow-Up. <i>Transplantation</i> , 2008, 86, 67-74.	1.0	59
46	A Cause-Specific Hazard Rate Analysis of Prognostic Factors Among 877 Adults Who Received Primary Orthotopic Liver Transplantation. <i>Transplantation</i> , 2007, 84, 155-165.	1.0	23
47	The Importance of Analyzing Graft and Patient Survival by Cause of Failure: An Example Using Pediatric Small Intestine Transplant Data. <i>Transplantation</i> , 2006, 81, 1133-1140.	1.0	16
48	A Randomized Long-Term Trial of Tacrolimus/Sirolimus versus Tacrolimus/Mycophenolate versus Cyclosporine/Sirolimus in Renal Transplantation: Three-Year Analysis. <i>Transplantation</i> , 2006, 81, 845-852.	1.0	96
49	A Randomized Trial of Three Renal Transplant Induction Antibodies: Early Comparison of Tacrolimus, Mycophenolate Mofetil, and Steroid Dosing, and Newer Immune-Monitoring. <i>Transplantation</i> , 2005, 80, 457-465.	1.0	204
50	A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. <i>Transplantation</i> , 2004, 77, 252-258.	1.0	140
51	A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. <i>Transplantation</i> , 2004, 77, 244-251.	1.0	115
52	The Use of Campath-1H as Induction Therapy in Renal Transplantation: Preliminary Results. <i>Transplantation</i> , 2004, 78, 426-433.	1.0	113